Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report released on Wednesday,Benzinga reports. They currently have a $21.00 price objective on the stock.

Other equities analysts also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, HC Wainwright raised their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.03 on Wednesday. The stock has a 50 day simple moving average of $3.37 and a 200 day simple moving average of $3.13. Trevi Therapeutics has a 52-week low of $1.27 and a 52-week high of $4.68. The firm has a market capitalization of $309.77 million, a PE ratio of -9.16 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the company posted ($0.08) earnings per share. Equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in Trevi Therapeutics by 38.8% in the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after purchasing an additional 49,884 shares during the last quarter. Rhumbline Advisers grew its position in Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock worth $224,000 after purchasing an additional 23,263 shares during the period. American Century Companies Inc. grew its position in shares of Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after acquiring an additional 7,902 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Trevi Therapeutics by 217.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after acquiring an additional 49,475 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Trevi Therapeutics in the 2nd quarter valued at about $61,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.